InferX third quarter gross profit increases 75% to $283,806

NewsGuard 100/100 Score

InferX Corporation (OTCQB: NFRX), a market leader in next generation Predictive Analytics products and solutions for the defense, healthcare and intelligence communities, today announced financial results for the third quarter of fiscal year 2011, which ended September 30, 2011.

"It has been a tremendous year so far; we started to see acceleration in the growth of our company, our products, and our profitability.  The team has achieved many firsts during this period: a significant new billion dollar customer for implementing a budgeting and financial analysis solution; a new Director of Sales; the continuation of our government business expansion; new enhancements to our technology; significant strides in penetrating the healthcare sector through expected teaming arrangements with major systems integrators; and the preparation for the roll out of a new product in the multi-billion dollar healthcare market.  We believe that these significant accomplishments have us poised to launch the company to an exciting and higher level of revenues and profitability" said Vijay Suri, President and CEO.

Summary Operating Results

Through aggressive efforts, the Company's gross profit was $283,806, an increase of 75% or $121,257 from the same quarter in 2010.  This increase in gross profit created a gross profit margin of 31%, an increase of 113% from the same quarter in 2010.

The gross profit for the first nine months of 2011 was $924,721, an increase of 150% or $554,543 from the same nine months in 2010.  This increase in gross profit created a gross profit margin of 33%, an increase of 241% from the same nine month period in 2010.  These increases to both gross profit and gross profit margin were made possible by the Company's continued efforts to maximize revenue from direct labor employees rather than higher costing subcontractors and the reduction of low margin business.

The Company enjoyed a net income of $339,548, an increase of 252% from the net loss in the same quarter 2010.  Likewise the Company was able to reduce loss by 27% in the first nine months of 2011 when compared to the same period in 2010. Product enhancement and software development worth $39,519 took place in the third quarter and will continue in the future.  The Company is continuing to upgrade its product suite in response to several major potential customers' specifications and overall market needs.

Earnings (Loss) per share for the quarter was $0.02, a 209% improvement from the same period in 2010 and a 129% improvement from June 30, 2011. InferX's growth going forward is based upon an aggressive sales development plan; a comprehensive communications and marketing initiative; hiring of additional sales representatives and the expansion of our external business development functions.  InferX believes that these combined efforts will continue to significantly improve its revenue and bottom line in upcoming quarters.

Source:

InferX Corporation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Empowering Change: How Hologic is Shaping the Future of Women's Healthcare